This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 133 entries.
An important research project testing the targeted capabilities of our antimicrobial platform, conducted in collaboration with The University of Queensland, has been published in Communications Biology – a leading peer-reviewed journal by Nature Research. The research article titled “The antimicrobial potential of cannabidiol” reveals the unique mechanism through which synthetic cannabidiol can kill the bacteria […]
Oxford University is opening a new research institute dedicated to tackling resistance to antibiotics. The university says this is one of the the biggest rising threats to global health, already causing 1.5 million deaths per year worldwide. The institute will be funded by £100m donated by the Ineos chemical company. Click through to read the […]
Synthetic cannabidiol, better known as CBD, has been shown for the first time to kill the bacteria responsible for gonorrhoea, meningitis and legionnaires disease. The research collaboration between The University of Queensland and Botanix Pharmaceuticals Limited could lead to the first new class of antibiotics for resistant bacteria in 60 years. The UQ Institute for […]
Superbugs were this week labelled as “the next great health crisis of our time” and there are a few ASX stocks seeking to address it. Superbugs are bacteria, viruses, fungi and parasites immune to conventional antibiotics and pharmaceuticals. Yesterday, on the eve of World Antimicrobial Resistance Awareness Week, Monash University has warned superbugs could kill […]
“Is this just a projection…?” The narrator of this video asks, as she examines the possibility of a world devoid of effective antibiotics, a most precious resource. Due to “use, misuse, overuse” of antibiotics, a dire future is forecast. It is thought provoking, unnerving – but also deeply motivating to be part of global action […]
AusBiotech’s BiotechDispatch featured our BTX 1801 antimicrobial program update today. Read the full article here.
The Australian Government Department of Health has this week published a summary of funding and strategy measures announced to address antimicrobial resistance (AMR) in the recent 2020-21 Federal Budget. This includes $22.5m to address the priorities identified in Australia’s National Antimicrobial Resistance Strategy – 2020 & Beyond. Key areas, as quoted in this excerpt, include: […]
Botanix Pharmaceuticals (BOT) has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration’s (FDA) Office of Infectious Diseases. The meeting assessed the potential of initiating clinical development of the company’s BTX 1801 antimicrobial drug for preventing surgical site infections (SSIs) in the U.S. It also enabled the company to receive feedback […]
The Green Fund has published a summary of Botanix Pharmaceutical’s BTX 1801 announcement today, an update on the development pathway for our BTX 1801 antimicrobial product. Take a look at the article here.
Botanix (ASX:BOT) has today announced it has secured a clear development path from the FDA for its BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting. Our team will have more clinical data to share soon too – our BTX 1801 Phase 2a study in Perth is […]